Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2007

Rosetta and NYU Expand Collaboration to Include Heart Disease

  • Rosetta Genomics extended an existing collaboration with NYU School of Medicine to include research into congenital heart disease (CHD). Investigators will be screening for specific miRNA biomarkers and signatures that may be used to diagnose and target CHD in newborns.

    "It is now clear that miRNAs play a key role in controlling diverse aspects of cardiac development and response to disease," notes David B. Meyer, M.D., director of pediatric and congenital cardiothoracic surgery at NYU School of Medicine. "Rosetta Genomics' extensive knowledge and proprietary technologies in the miRNA field, coupled with our experience in CHD, is an excellent starting point for this collaboration."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »